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Summary 
Micropapillary carcinoma (MPC), a relatively rare histologic carcinoma observed in various 
organs, is associated with vascular invasion, nodal metastasis, and poor prognosis. MPC is 
different from papillary carcinoma as it has no fibrovascular core and is thus considered 
essentially hypovascular. MPCs are known to upregulate glucose transporter 1 (GLUT1) via 
the activation of a transcription factor, hypoxia-inducible factor (HIF)-1. Here we evaluated 
the expression of nutrient transporters in MPCs to gain a better understanding of the system 
used by MPCs to compensate for their intrinsic poor vascularity. We immunohistochemically 
evaluated 29 MPCs including breast (n=14), lung (n=8), gastrointestinal tract (n=5), and 
urinary tract cancers (n=2) and compared them with non-micropapillary control cancers 
(n=32) regarding the expression of amino acid (ASCT1, ASCT2, LAT1, and SNAT1) and 
glucose (GLUT1, GLUT2) transporters. Each section was scored by the staining intensity (0Ð
3) multiplied by the occupying area (0Ð10), with a possible range 0Ð30. The average scores of 
the MPC and control groups were compared by Student's or Welch's t-test according to the 
homoscedasticity. The MPC group showed markedly and significantly higher scores for 
ASCT1 (p=0.007), ASCT2 (p=0.001), GLUT1 (p<0.001), and GLUT2 (p<0.001), whereas no 
significant between-group difference was observed in the LAT1 and SNAT1 scores. In 
conclusion, MPC could be associated with the upregulation of several nutrient transporters, 
which may contribute to the malignant potential by supporting the survival of cancer cells. 
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Introduction 
Since the first report by Luna-Mor et al. in 1994, micropapillary carcinoma (MPC) or 
micropapillary components in several cancers have been a well-known risk factor for blood 
and/or lymph vessel invasion, lymph node metastasis, and mortality (Nagano et al., 2010; 
Willis et al., 2014; Lee et al., 2015; Liu et al., 2015).
 
MPCs have been documented in the 
breast, the lung, the gastrointestinal (GI) tract, and the urothelial cancers, where the presence 
of MPC is nearly always a sign of poor prognosis (Guzińska-Ustymowicz et al., 2014; Zhang 
et al., 2015). By definition, an MPC forms delicate papillary tufts devoid of central 
fibrovascular cores, which makes these papillary tufts different from "true" papillae with 
cores. Micropapillae are occasionally floating in the lacunar-like space in the fibrous stroma 
with their apical surfaces outwards; this is known as the "inside-out" growth pattern (Troxell, 
2014). 
For cancers to progress, vascularity within or around the tumor is thought to be 
important, since proliferating cancer cells need large amounts of nutrients (Carmeliet and 
Jain, 2000). MPCs are suspected to be always under a condition of poor nutrition and hypoxia 
due to their lack of a fibrovascular core (Nagano et al. 2010). However, MPCs are a highly 
aggressive cancer, and their massive necrosis is rarely observed. We speculated that MPCs 
have evolved some compensatory system(s) against the poor blood and nutrition supply, and 
that such compensatory system(s) may contribute to the aggressive behavior and poor 
prognosis of MPCs. 
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Glucose transporter 1 (GLUT1), a major glucose transporter of somatic cells, has been 
shown to be upregulated in MPCs via the activation of the transcription factor hypoxia-
inducible factor (HIF)-1 (Nagano et al., 2010; Koh et al., 2017). HIF-1 controls the 
angiogenesis and accommodation of various cellular activities to hypoxia (Wang and 
Semenza, 1993; Carmeliet and Jain, 2000). GLUT1 is a representative HIF-1 target gene 
product. An upregulation of GLUT1 can substantially improve the uptake of glucose, and it 
supports energy production via accelerated glycolysis. Proliferating cancer cells also require 
building blocks such as amino acids and lipids other than sugar and oxygen, and several 
amino acid transporters are known to be upregulated in various cancers (Yanagida et al., 2001; 
Fuchs and Bode, 2005; Kaira et al., 2009; Fan et al., 2010). 
However, the differences in amino acid transporter expression among different 
carcinoma histologic subtypes have not been fully examined. We hypothesized that MPCs 
may compensate for their poor vascularity via upregulations of amino acid and sugar 
transporters such as alanine/serine/cysteine/threonine transporter 1 (ASCT1), ASCT2, L-type 
amino acid transporter 1 (LAT1), sodium-coupled neutral amino acid transporter 1 (SNAT1), 
GLUT1, and GLUT2 with more significant augmentation compared to non-MPC cancers, 
which leads to the MPCs' aggressiveness. 
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Materials and Methods 
Case selection 
We retrospectively analyzed surgically resected specimens that had been histologically 
diagnosed as MPCs or as carcinomas with MPC components at the Department of Pathology, 
Tottori University Hospital (Yonago, Japan) during the years 2004Ð2016, regardless of the 
patients' age, sex or tumor stage (Table 1). Small cancers with an invasion diameter <1 cm 
and mixed MPC component <10% were excluded. Cases with suspicious antigen 
degeneration (e.g., insufficient staining of inner positive controls in an immunohistochemical 
procedure) were also excluded. The final total of 29 MPC cases included 14 breast cancers, 8 
lung cancers, 5 gastrointestinal (GI) cancers, and 2 urothelial cancers. Five of the breast 
cancers were pure MPCs, and the remaining 24 MPCs were mixed cancers with conventional 
histological subtypes. We also selected 32 control cases from the above-mentioned organs. 
Control cases of lung adenocarcinoma were selected in order to not deviate from the specific 
histological subtype. 
Written informed consent for their materials to be used was obtained from each patient, 
and the study was approved by the Ethics Committee of the Faculty of Medicine, Tottori 
University (approval no. 1707A071; July 13, 2017). 
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Immunohistochemistry and scoring 
The primary antibodies used in this study are listed in Table 2. The upregulation of all 
of the target transporters in cancers has been reported. Paraffin-embedded formalin-fixed 
tissue of the cancers were cut into 4-µm slices and placed on silane-coated glass slides. After 
being baked at 70Υ for 30 min, the sections were deparaffinized and hydrated in xylene and a 
concentration-gradient ethanol-water system. Endogenous peroxidase activity was quenched 
in 30% aqueous H2O2 with methanol (10% v/v). Sections were heated to 95Υ in pH 6.0 citrate 
buffer for 20 min for antigen retrieval, then cooled to room temperature. After blocking with 
Block Ace solution (4 g/100 ml; DS Pharma Biomedical, Osaka, Japan), the sections were 
incubated with each primary antibody at 4Υ overnight. 
After being washed with phosphate-buffered saline (PBS) containing Tween, the slides 
were incubated with secondary antibody (EnVision Dual link system; Dako, Glostrup, 
Denmark) for 30 min. Antigen-antibody complex was visualized by a Liquid DAB+ Substrate 
Chromogen System (Dako), then counterstained with hematoxylin. 
For a quantitative evaluation of the expression of each transporter, every slide was 
scored based on its average staining intensity (1: weak, 2: moderate, 3: strong) multiplied by 
the positive ratio per tumor area (0: 0%, 1: 1%Ð10%, 2: 11%Ð20%, 3: 21%Ð30%, 4: 31%Ð
40%, 5: 41%Ð50%, 6: 51%Ð60%, 7: 61%Ð70%, 8: 71%Ð80%, 9: 81%Ð90%, 10: 91%Ð100%), 
resulting in a score from 0 to 30. For the MPC cases, only the MPC components were 
evaluated, and for the non-MPC cases (CONT), all the cancer areas were evaluated. Two 
H
IS
TO
LO
G
Y
 A
N
D
 H
IS
TO
P
A
TH
O
LO
G
Y
 
(n
on
-e
di
te
d 
m
an
us
cr
ip
t)
8 
pathologists (KN and KM) scored the slides individually, and the similarity of the scores by 
the two observers was statistically confirmed. KM was blinded to the purpose of this study 
while scoring. 
 
Statistical analyses 
We first examined the homoscedasticity of the score distribution in the MPC and 
control groups by using the Levine test. If the score distribution was found to be 
homoscedastic, the average scores of the MPC versus control cases were compared with 
Student's t-test. When the distribution was not homoscedastic, the average scores were 
compared with Welch's t-test. The difference was considered significant when p<0.05. The 
Statistical Package for Social Sciences ver. 24 (IBM SPSS Statistics; IBM, Armonk, NY) was 
used in all statistical analyses. 
 
Results 
The staining patterns of the transporters 
Representative staining patterns of the respective transporters are shown in Figure 1. 
ASCT1 showed a linear staining pattern on the basolateral membrane. Weak to moderate 
cytoplasmic staining was often observed. Plasma cells served as inner positive controls. 
ASCT2 showed fine granular cytoplasmic staining with faint membranous staining. 
Adipocytes served as inner positive controls. 
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GLUT1 showed intense membranous staining. Erythrocytes served as inner positive 
controls. GLUT2 showed only a finely granular cytoplasmic staining pattern, in contrast to 
the membranous staining of hepatocytes in our examination determining the optimal 
conditions for staining. LAT1 showed a linear staining pattern along the basolateral 
membrane. Vascular smooth muscle cells served as inner positive controls. SNAT1 showed a 
coarse granular cytoplasmic staining pattern. In the breast cancers, non-neoplastic ductal 
epithelium served as inner positive controls. 
 
The staining scores of the MPC vs. control cases in the respective organs 
The staining scores of the MPCs and control cases are summarized in Table 3. The 
ASCT1, ASCT2, GLUT1, and GLUT2 scores were significantly higher in the MPC group. No 
significant difference was revealed in the LAT1 or SNAT1 scores (Fig. 2). 
 
Discussion 
GLUT1 upregulation was predictable considering MPCs' intrinsic hypoxia due to a 
structural factor. Higher GLUT1 expression in MPCs was histologically confirmed in lung 
adenocarcinomas (Nagano et al., 2010; Koh et al., 2017), and a facilitated uptake of 2-
18
fluoro-deoxy-D-glucose (
18
FDG) by lung MPCs on positron emission tomography has also 
been reported (Nakamura et al., 2015). Our present findings indicate that the augmented 
expression of GLUT1 in MPC is an almost universal event, not restricted to lung cancer. 
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GLUT2 is a glucose and fructose transporter with high capacity and low affinity that is 
thought to act as a glucose sensor molecule of hepatocytes and islet β cells of the pancreas. 
GLUT2 is also thought to facilitate glucose absorption at the small intestine when the glucose 
level is significantly elevated, e.g., after a meal (Mueckler and Thorens, 2013). GLUT2 is also 
known to act as a glucosamine transporter (Uldry et al., 2002), but it is unclear whether this 
role is beneficial to MPC. Although GLUT2 upregulation in pancreatic and liver cancers is 
well known, its overexpression in cancers in extra-hepatobiliary organs has not been well 
investigated (Godoy et al., 2006; Kim et al., 2017). It is intriguing that GLUT2 is usually 
detected in the cancer cell cytoplasm and not as the membranous staining of normal control 
cells such as human hepatocytes. It is reported that insulin internalizes membrane-bound 
GLUT2 to the cytosol (Tobin et al., 2008). Whether this membrane-to-cytoplasm translocation 
of GLUT2 has some relation to cancer activities remains to be solved. 
Several amino acid transporters such as ASCT2 and LAT1 are often upregulated in 
cancers (Yanagida et al., 2001; Fuchs and Bode, 2005; Kaira et al., 2009; Fan et al., 2010; 
Wang et al., 2013). In fact, in the present study the scores for the ASC transporters (ASCT1, 
ASCT2) were markedly higher in the MPC group. ASCT2, a gene product of SLC1A5, is a 
member of the ASC system which transports neutral amino acids such as Ala, Ser, Cys, and 
glutamine (Fuchs and Bode, 2005). This transporter is thought to be controlled by another 
hypoxia-sensing factor (HIF2α) to some extent, via a transduction pathway using lactate as a 
signal molecule (Prez-Escuredo et al., 2016). ASCT2 upregulation may thus be reasonable in 
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hypoxic and presumably glycolysis-dependent MPCs. 
LAT1 is known to be overexpressed in many cancers (Yanagida et al., 2001; Kaira et 
al., 2009; Fan et al., 2010), and its overexpression correlates with worse prognosis. However, 
no significant difference in the expression of LAT1 was demonstrated in the present study. 
Although SNAT1 is thought to have a critical role in cancers (Wang et al., 2013),
 
no 
significant difference in the SNAT1 score was demonstrated herein. These transporters' 
overexpression may be related to the cancer activity itself and have no association with MPCs' 
structure or their compensatory system. 
Our present findings suggest that MPCs can efficiently compensate for their hypoxia 
and poor nutrition by upregulating several nutrient transporters, and the hypoxia itself can be 
quite beneficial for the MPCs' utilization of nutrients from the environment. In addition, the 
cell division of MPCs has been suggested to be less active compared to other histological 
subtypes (Ishii et al., 2011; Zhang et al., 2015), which may make MPCs more "economic," 
enabling them to survive severe conditions until they reach a more suitable field for tumor 
growth. However, an immunohistochemical analysis is merely a subjective assessment, and 
we examined a relatively small number of cases in the present study. Objective evaluations 
using molecular biological approaches with larger collections of MPC cases are needed. 
In conclusion, this is the first study to investigate the difference in the metabolic state of 
cancers, focusing on MPC, a specific histological subtype. We speculate that respective 
histological subtypes may differ not only in proliferation and/or invasion activity, but also in 
H
IS
TO
LO
G
Y
 A
N
D
 H
IS
TO
P
A
TH
O
LO
G
Y
 
(n
on
-e
di
te
d 
m
an
us
cr
ip
t)
12 
oxygenation, nutrition, and secondary compensatory systems. Our present findings also 
demonstrate an example of cancer cell accommodation to the environment. Closer 
investigations of the relationship between histological subtypes and metabolic states will lead 
us to a better understanding of complex cancer behavior and more effective anti-cancer 
strategies. 
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Table 1. Clinicopathological characteristics of the MPC and control cases  
  Case No. M/F Age, yrs 
Cases with positive 
LN metastasis (%) 
Breast  29 0/29 64.1/60±15.6 10/29 (34.5) 
 MPC 14 0/14 66.1/67±16.9 8/14 (57.1) 
 Control 15 0/15 62.3/59±14.5 2/15 (13.3) 
Lung  15 10/5 68.5/70±8.1 5/15 (33.3) 
 MPC 8 6/2 68.4/71±7.5 2/8 (25) 
 Control 7 4/3 68.7/70±10 3/7 (42.9) 
GI  10 7/3 68.3/67±7.3 6/10 (60.0) 
 MPC 5 4/1 66.0/66±6.7 4/5 (80) 
 Control 5 3/2 70.6/68±7.8 2/5 (40) 
Urothelial  7 5/2 73.2/74.5±7.2 2/7 (28.6) 
 MPC 2 1/1 69.4/71±5.9 1/2 (50.0) 
 Control 5 4/1 77.0/76±6.8 1/5 (20.0) 
GI, gastrointestinal; LN, lymph node; M/F, male/female; MPC, micropapillary carcinoma. 
Patient ages are presented as the mean/median ± std. dev. 
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Table 2. Primary antibodies used  
Target Product name Species/type Source Dilution 
ASCT1 ab204348 Rabbit/poly Abcam* 1:40 
ASCT2 ab84903 Rabbit/poly Abcam 1:800 
GLUT1 ab15309 Rabbit/poly Abcam 1:200 
GLUT2 ab85715 Mouse/mono Abcam 1:50 
LAT1 Anti-Human LAT1 Polyclonal Antibody Rabbit/poly Transgenic** 1:50 
SNAT1 ab60145 Rabbit/poly Abcam 4 µg/ml 
*Abcam, Cambridge, UK. **Transgenic, Kumamoto, Japan. 
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Table 3. Comparison of respective transporters' scores in the MPC and control cases 
Transporter Type Mean SD* SE** of the mean p-value 
ASCT1 
MPC 5.31 6.404 1.189 
0.007 
CONT 1.66 2.404 0.425 
ASCT2 
MPC 6.69 5.245 0.974 
0.001 
CONT 2.50 3.302 0.584 
GLUT1 
MPC 12.86 7.120 1.322 
<0.001 
CONT 5.28 5.069 0.896 
GLUT2 
MPC 11.10 6.472 1.202 
<0.001 
CONT 5.16 5.131 0.907 
LAT1 
MPC 4.14 6.828 1.268 
0.211 
CONT 2.34 3.525 0.623 
SNAT1 
MPC 9.28 6.708 1.246 
0.106 
CONT 6.59 6.069 1.073 
Frequency: MPC = 29, CONT = 32. * Standard deviation. ** Standard error. 
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Figure Legends 
Fig. 1. The staining patterns of the transporters. Invasive MPCs with positive staining are shown 
(original magnification; 400⋅, scale bar = 40 µm). a: ASCT1: Linear staining along the basolateral 
membrane and faint cytoplasmic stain. b: ASCT2: Faint granular cytoplasmic stain. c: GLUT1: 
Intense membranous stain. d: GLUT2: Fine granular cytoplasmic stain. e: LAT1: Linear basolateral 
membranous stain. f: SNAT1: Coarse granular cytoplasmic stain. 
 
Fig. 2. Comparison of transporter scores of the MPCs and non-MPCs. The average transporter score 
of each group was compared using Student's t-test or Welch's t-test, according to the 
homoscedasticity of the data. *p<0.01. 
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